| Literature DB >> 31772819 |
Luis Michel Alonso Martinez1,2,3, François Harel2,3,4, Myriam Létourneau5, Vincent Finnerty3, Alain Fournier5, Jocelyn Dupuis3,6, Jean N DaSilva1,2,4.
Abstract
Circulating adrenomedullin (AM) levels are elevated in several cardiovascular diseases, including pulmonary vascular diseases causing pulmonary hypertension. To date the perfusion agent 99mTc-albumin macroaggregates (MAA) is the only approved radiopharmaceutical used for imaging of pulmonary circulation. Unlike 99mTc-MAA, imaging the AM receptors involves a molecular process dependent on the density of the receptors and the affinity of specific radioligands. The AM receptors are abundantly distributed in lung capillaries and its integrity provides protection in the development of pulmonary vascular diseases. This review summarizes the development and characterization of radioligands for in vivo imaging of AM receptors as an early predictor of the onset of a pulmonary vascular disease. AJNMMIEntities:
Keywords: PET; Pulmonary arterial hypertension; SPECT; adrenomedullin radiotracers; lung microcirculation; pulmonary embolism
Year: 2019 PMID: 31772819 PMCID: PMC6872478
Source DB: PubMed Journal: Am J Nucl Med Mol Imaging